Myoblasts are the primary effector cells that play crucial roles in myogenesis and muscle regeneration following injury. However, isolating purified primary myoblasts from murine skeletal muscle poses challenges for junior researchers. Here, we present a simplified, low-risk, and optimized protocol for the extraction and enrichment of these myogenic progenitor cells. Additionally, we demonstrate that, compared to F10 (Ham's F-10)-based medium, DMEM (Dulbecco's Modified Eagle's Medium)-based differentiation medium provides a more conducive environment for myoblasts differentiation. This enhancement improves the efficiency of myofiber formation and the expression of myogenic markers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s44307-025-00060-0 | DOI Listing |
Purinergic Signal
March 2025
Université Côte dAzur, CNRS, INSERM, IRCAN, Nice, France.
Over the past few years, transcriptomics has emerged as a pillar for modern scientific research, enabling the comprehensive profiling of gene expression. The availability of large-scale public datasets, such as NCBI Gene Expression Omnibus, International Cancer Genome Consortium, and The Cancer Genome Atlas, has significantly boosted many scientific discoveries. However, to analyze and interpret these vast datasets, sophisticated bioinformatic tools are often necessary.
View Article and Find Full Text PDFDiabetologia
March 2025
Population Health Research Institute, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK.
Aims/hypothesis: Biennial, as opposed to annual, screening for diabetic retinopathy was recently introduced within England for those considered to be at 'low risk'. This study aims to examine the impact that annual vs biennial screening has on equitable risk of diagnosis of sight-threatening diabetic retinopathy (STDR) among people at 'low risk' and to develop an amelioration protocol.
Methods: In the North East London Diabetic Eye Screening Programme (NELDESP), 105,083 people without diabetic retinopathy were identified on two consecutive screening visits between January 2012 and September 2023.
Nat Protoc
March 2025
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
mRNA-based therapies have emerged as a cutting-edge approach for diverse therapeutic applications. However, substantial barriers exist that hinder scientists from entering this research field, including the technical complexity and multiple potential workflows available for formulating and evaluating mRNA lipid nanoparticles (LNPs). Here we present an easy-to-follow and step-by-step guide for mRNA LNP formulation, characterization and in vitro and in vivo evaluation that could lower these barriers, facilitating entry for scientists in academia, industry and clinical settings into this research space.
View Article and Find Full Text PDFAdv Biotechnol (Singap)
March 2025
Biotherapy Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China.
Myoblasts are the primary effector cells that play crucial roles in myogenesis and muscle regeneration following injury. However, isolating purified primary myoblasts from murine skeletal muscle poses challenges for junior researchers. Here, we present a simplified, low-risk, and optimized protocol for the extraction and enrichment of these myogenic progenitor cells.
View Article and Find Full Text PDFCancer Imaging
March 2025
Department of Ultrasound, The First Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province, 110001, China.
Background: In 2020, we introduced the Greater Omentum Imaging-Reporting and Data System (GOI-RADS), a novel classification system related to peritoneal lesions. However, its clinical application remained unvalidated.
Objective: This study aimed to validate GOI-RADS, optimize its parameters for a new grading system, and explore its clinical usefulness.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!